25/11/2010

Avexa secures meeting with US Food and Drug Administration on apricitabine

“This meeting with the FDA marks a very important opportunity for Avexa and ATC. We will be able to present the most recent data from our Phase II/III to the Agency and discuss possible paths forward for ATC."

Melbourne, Australia, Wednesday 24 November, 2010: Australian biotechnology company Avexa Limited [ASX:AVX] today announced that it has secured a meeting with the US Food and Drug Administration to discuss the company’s anti-HIV drug apricitabine (ATC).

The meeting is scheduled to take place in the first quarter of calendar 2011.

Joe Baini, Chairman of Avexa, said: “This meeting with the FDA marks a very important opportunity for Avexa and ATC. We will be able to present the most recent data from our Phase II/III to the Agency and discuss possible paths forward for ATC."

About Avexa Limited: Avexa Limited is a Melbourne-based biotechnology company with a focus on discovery, development and commercialisation of small molecules for the treatment of infectious diseases. Avexa’s key projects include apricitabine (ATC) for the treatment of drug-resistant HIV, an HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections.

Avexa Limited

http://www.avexa.com.au/

http://www.avexa.com.au/freestyler/files/Avexa%20secures%20FDA%20meeting%20on%20ATC.pdf

Share this page

More...

DISCLAIMER

The EATG is not responsible for the content of this article. It does not necessarily reflect EATG views or opinions.

FAIR USE NOTICE

The information above may contain copyrighted material which has not always been specifically authorised by the copyright owner. Such material is made available for educational purposes to advance the understanding of scientific, ethical, legal and social issues. It is believed that this constitutes a 'fair use' of any such copyrighted material. This material is distributed without profit via the subscription to the daily digest.